Filing Overview
Issuer: I-MAB (Nasdaq: IMAB), a foreign private issuer. The supplied filing is a Form 6-K for August 2022, dated August 16, 2022. The request metadata identifies “Novabridge Biosciences,” but the filing itself identifies I-MAB.
The filing reports an amendment to I-MAB’s global strategic partnership and license agreement with AbbVie concerning anti-CD47 antibody therapies.
Business and Strategic Update
- I-MAB and AbbVie will continue collaborating on the global development of anti-CD47 antibody therapies.
- I-MAB may receive up to US$1.295 billion in development, regulatory, and sales milestone payments for certain new anti-CD47 antibodies currently in development.
- The agreement also provides tiered royalties ranging from mid- to high-single-digit percentages on global net sales outside Greater China for certain new anti-CD47 antibodies.
- For other licensed products, the previously disclosed milestone and royalty terms remain applicable.
- I-MAB retains exclusive rights to develop and commercialize all licensed products in Greater China.
Financial Metrics and Liquidity
- The filing does not provide current-period revenue, profit, operating cash flow, margins, debt, or detailed liquidity metrics.
- I-MAB reported US$671 million in cash, cash equivalents, and short-term investments as of December 31, 2021.
- Management stated that this cash position supports ongoing and planned development of lemzoparlimab and other late-stage clinical assets.
- The filing does not clearly state whether any milestone payment had been received or recognized as revenue as of the filing date.
Material Changes and Clinical Development
- AbbVie will discontinue the global Phase 1b study of lemzoparlimab in combination with azacitidine and venetoclax in patients with MDS and AML.
- The company stated that the discontinuation was not based on any specific or unexpected safety concerns.
- I-MAB plans to focus near term on initiating a Phase 3 trial of lemzoparlimab in MDS patients in China.
- The planned Phase 3 program is supported by Phase 2 safety and efficacy data for lemzoparlimab combined with azacitidine in higher-risk MDS patients; detailed data were scheduled for presentation at the September 2022 ESMO Congress.
- Phase 1 and Phase 2 studies in the United States and China had enrolled nearly 200 patients and, according to the company, showed a good safety profile without a priming-dose regimen.
Outlook, Risks, and Unusual Items
- The potential milestone payments and royalties are contingent on development, regulatory, and commercial achievements and are not guaranteed.
- Forward-looking statements include the potential progress of the AbbVie collaboration, clinical-trial initiation and completion, regulatory approval, and commercial success of lemzoparlimab and other candidates.
- Key risks include failure to demonstrate safety or efficacy, unfavorable regulatory decisions, inability to achieve commercial success, intellectual-property risks, reliance on third parties, limited operating history, and potential need for additional funding.
- COVID-19 could adversely affect clinical development, commercial activities, and other operations.
- The filing states that AbbVie’s Phase 1b discontinuation was not prompted by specific or unexpected safety concerns, but it nevertheless represents a reduction in the scope of the global development program.
Investor Verification Checklist
- Verify the final terms of the amendment, including which products are subject to the US$1.295 billion milestone opportunity and the applicable royalty rates.
- Determine whether any upfront, milestone, or other collaboration payments were received or recognized in subsequent financial statements.
- Review the ESMO 2022 presentation and subsequent clinical updates for the lemzoparlimab Phase 2 data and Phase 3 progress.
- Confirm the status, financing, and regulatory plans for the planned China MDS Phase 3 trial.
- Assess subsequent filings for changes to the AbbVie collaboration, clinical strategy, cash balance, funding needs, and development risks.